-
公开(公告)号：US20040039035A1
公开(公告)日：2004-02-26
申请号：US10654112
申请日：2003-09-02
Applicant: Tularik Inc. , ChemoCentryx, Inc.
Inventor： Tassie Collins , Daniel J. Dairaghi , Hossen Mahmud , Brian E. McMaster , Julio C. Medina , Thomas J. Schall , Feng Xu , Xuemei Wang
IPC: A61K031/426 , A61K031/4245 , A61K031/381 , A61K031/18 , A61K031/34
CPC classification number: C07D417/12 , A61K31/00 , A61K31/265 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/4245 , A61K31/426 , C07D277/42 , C07D277/82 , C07D513/04
Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
Abstract translation: 提供了结合CCR4趋化因子受体的化合物和组合物，其可用于治疗与CCR4活性相关的疾病，例如接触性超敏反应。
-
公开(公告)号：US20040162282A1
公开(公告)日：2004-08-19
申请号：US10732897
申请日：2003-12-09
Applicant: ChemoCentryx, Inc.
Inventor： Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subhabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
IPC: A61K031/53 , A61K031/522 , A61K031/506 , A61K031/496 , C07D473/02 , C07D43/02
CPC classification number: C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/56 , C07D235/06 , C07D249/12 , C07D257/04 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D409/04 , C07D473/34
Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
-
Patent Agency Ranking
公开(公告)号：US20020173524A1
公开(公告)日：2002-11-21
申请号：US09975566
申请日：2001-10-11
Applicant: Tularik Inc.
Inventor： Tassie Collins , Daniel J. Dairaghi , Hossen Mahmud , Brian E. McMaster , Julio C. Medina , Thomas J. Schall , Feng Xu , Xuemei Wang
IPC: A61K031/426 , A61K031/4245 , A61K031/381 , A61K031/36 , A61K031/351 , A61K031/265 , A61K031/18
CPC classification number: C07D417/12 , A61K31/00 , A61K31/265 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/4245 , A61K31/426 , C07D277/42 , C07D277/82 , C07D513/04
Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
Abstract translation: 提供了结合CCR4趋化因子受体的化合物和组合物，其可用于治疗与CCR4活性相关的疾病，例如接触性超敏反应。
-
公开(公告)号：US20040082571A1
公开(公告)日：2004-04-29
申请号：US10460752
申请日：2003-06-11
Applicant: ChemoCentryx, Inc.
Inventor： Andrew M.K. Pennell , James B. Aggen , J.J. Kim Wright , Subrabrata Sen , Brian E. McMaster , Daniel Joseph Dairaghi
IPC: A61K031/551 , A61K031/53 , A61K031/52 , A61K031/496 , A61K031/501 , C07D473/14 , C07D43/02
CPC classification number: C07D473/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/56 , C07D235/06 , C07D249/12 , C07D257/04 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D409/04
Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Abstract translation: 提供了作为CCR1受体的有效拮抗剂的化合物，并且在用于CCR1的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基哌嗪衍生物，并且可用于药物组合物，用于治疗CCR1介导的疾病的方法，以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号：US20030119854A1
公开(公告)日：2003-06-26
申请号：US10279353
申请日：2002-10-23
Applicant: ChemoCentryx, Inc.
Inventor： Thomas J. Schall , Daniel J. Dairaghi , Brian E. McMaster
IPC: A61K031/517 , A61K031/4709 , A61K031/47 , C07D239/72 , C07D43/02 , C07D217/22 , C07D41/02
CPC classification number: C07D239/91
Abstract: Compounds and compositions are provided that bind to the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.
Abstract translation: 提供了与CXCR3趋化因子受体结合的化合物和组合物，其可用于治疗与CXCR3活性相关的疾病，如多发性硬化症。
-
公开(公告)号：US20030114423A1
公开(公告)日：2003-06-19
申请号：US10233336
申请日：2002-08-29
Applicant: ChemoCentryx, Inc.
Inventor： Brian E. McMaster , Thomas J. Schall , Mark Penfold , J.J. Wright , Daniel J. Dairaghi
IPC: A61K031/675 , A61K031/5377 , A61K031/496 , A61K031/4709 , A61K031/4178 , A61K031/454
CPC classification number: C07D207/08 , A61K31/075 , A61K31/135 , A61K31/4709 , C07D207/27 , C07D211/14 , C07D211/26 , C07D231/12 , C07D241/04 , C07D295/088 , C07D295/096 , C07D295/135 , C07D295/155 , C07D453/04
Abstract: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: 1 wherein the subscripts m and n are each independently integers from 1 to 2; and the R groups are as defined in the specification.
Abstract translation: 提供了使用具有下式的化合物治疗CMV和CMV相关疾病的方法：其中下标m和n各自独立地为1至2的整数; 并且R基团如说明书中所定义。
-
公开(公告)号：US20020132836A1
公开(公告)日：2002-09-19
申请号：US09975567
申请日：2001-10-11
Applicant: ChemoCentryx Inc.
Inventor： Daniel J. Dairaghi , Brian E. McMaster , Thomas J. Schall
IPC: A61K031/426 , A61K031/4245 , A61K031/381 , A61K031/357 , A61K031/341 , A61K031/18
CPC classification number: C07D417/12 , A61K31/00 , A61K31/18 , A61K31/265 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/4245 , A61K31/426 , C07D277/42 , C07D277/82 , C07D513/04
Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
Abstract translation: 提供了结合CCR4趋化因子受体的化合物和组合物，其可用于治疗与CCR4活性相关的疾病，例如接触性超敏反应。
-
-
-
-
-
-
Search Results
7
records
(took 0.023 seconds)
